Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.

Anderson RT, Keysar SB, Bowles DW, Glogowska MJ, Astling DP, Morton JJ, Le P, Umpierrez A, Eagles-Soukup J, Gan GN, Vogler BW, Sehrt D, Takimoto SM, Aisner DL, Wilhelm F, Frederick BA, Varella-Garcia M, Tan AC, Jimeno A.

Mol Cancer Ther. 2013 Oct;12(10):1994-2005. doi: 10.1158/1535-7163.MCT-13-0206. Epub 2013 Jul 19.

2.

Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.

Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE.

Clin Cancer Res. 2011 Aug 1;17(15):5016-25. doi: 10.1158/1078-0432.CCR-11-0050. Epub 2011 Jun 14.

3.

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.

Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA Jr, Raben D.

Mol Cancer Ther. 2007 Jun;6(6):1683-91. Epub 2007 May 31.

4.

Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor.

Qi L, Nett TM, Allen MC, Sha X, Harrison GS, Frederick BA, Crawford ED, Glode LM.

Cancer Res. 2004 Mar 15;64(6):2090-5.

5.

GnRH-PAP hormonotoxin targets cytotoxicity to prostate cancer cell lines.

Qi L, Nett TM, Allen MC, Sha X, Harrison GS, Frederick BA, Glode LM.

Urol Res. 2003 Dec;31(6):374-7. Epub 2003 Sep 13.

PMID:
13680022
6.

Futile medical care.

Frederick BA.

Conn Med. 1995 Mar;59(3):163-70. No abstract available.

PMID:
7729139

Supplemental Content

Loading ...
Support Center